Core Insights - The medical services sector experienced a significant increase of 4.77% on January 5, with Sanbo Brain Science leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Medical Services Sector Performance - Sanbo Brain Science (301293) closed at 70.78, with a rise of 20.01% and a trading volume of 106,700 shares, amounting to a transaction value of 755 million [1] - Likang Life (300143) saw a closing price of 11.38, increasing by 15.18% with a trading volume of 473,200 shares, totaling 518 million [1] - Chengdu Xian Dao (688222) closed at 26.14, up 11.47%, with a trading volume of 277,100 shares, resulting in a transaction value of 704 million [1] - Other notable performers include She Nei Medical (301060) at 10.20 (+10.27%), International Medical (000516) at 4.72 (+10.02%), and Zhaoyan New Drug (603127) at 38.51 (+10.00%) [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.028 billion from institutional investors, while retail investors contributed a net inflow of 174 million [2] - Notable net inflows from institutional investors include Zhaoyan New Drug (603127) with 235 million and Sanbo Brain Science (301293) with 214 million [3] - Conversely, retail investors showed significant outflows from several stocks, including Sanbo Brain Science (301293) with a net outflow of 136 million and Likang Life (300143) with 27.9 million [3]

Core Insights - The health service industry aims to create a favorable organizational environment by providing safe, effective, convenient, and affordable basic medical and public health services to meet various health needs of residents. The demand for health-related products and services is rapidly increasing due to social progress and changes in lifestyle [1][7]. Industry Overview - The health service industry encompasses medical services, health management, health insurance, and related services, involving pharmaceuticals, medical devices, health products, and fitness products [4]. - The industry has experienced rapid growth in China, with the market size increasing from 6.37 trillion yuan in 2018 to an expected 9.55 trillion yuan by 2024, representing a compound annual growth rate of 6.98%. The "Healthy China 2030" plan projects the total market size to reach 16 trillion yuan by 2030, indicating significant growth potential [1][8]. Development History - The development of China's health service industry can be divided into four stages: 1. 1949-1990: Health check-ups were primarily hospital services focused on disease detection rather than prevention. 2. 1991-2000: Independent health check-up service institutions began to emerge in cities like Beijing. 3. 2001-2010: The introduction of Western health service concepts and rapid market demand growth led to the fast development of health service institutions. 4. 2011-present: Increased focus on medical information technology and service upgrades has improved the capabilities of health service institutions [4][5]. Relevant Policies - Recent government policies aim to optimize resource allocation, enhance preventive interventions, and improve service accessibility, which helps control the rapid growth of medical costs and reduce the disease burden on families and society. For instance, the National Health Commission issued a notice in February 2025 to address public health concerns and improve service efficiency [6]. Industry Structure and Key Companies - The operational models of health service institutions in China are diverse, including: 1. Hospital-based models leveraging brand and client resources. 2. Independent medical models with self-owned brands and facilities. 3. Health management models centered on health check-ups. 4. Comprehensive information platform models connecting online and offline services [8]. - Major companies in the health service industry include: - Meinian Health Industry Holdings Co., Ltd. - Tongce Medical Co., Ltd. - Ruici Medical Service Holdings Co., Ltd. - Ciming Health Checkup Management Group Co., Ltd. - Aikang Guobin Health Checkup Management Group Co., Ltd. [2][3][9]. Trends in Health Services - The future of health services will focus on personalized and precise care, moving from a "one-size-fits-all" approach to individualized health management based on personal data [11]. - Service delivery will become decentralized, extending beyond traditional healthcare facilities to community and home settings, enhancing accessibility and convenience [12]. - Payment models will evolve from fee-for-service to value-based care, with insurance companies and service providers collaborating to create innovative health products [13].

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Tongce Medical (600763) as of December 29, 2025, with a closing price of 40.55 yuan, reflecting a decrease of 0.93% [1] - The company reported a main revenue of 2.29 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 2.56% [2] - The net profit attributable to shareholders for the same period was 514 million yuan, up 3.16% year-on-year, while the net profit excluding non-recurring items was 509 million yuan, increasing by 3.09% [2] Group 2 - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, which is a 2.34% year-on-year increase [2] - The net profit attributable to shareholders for Q3 2025 was 192 million yuan, reflecting a year-on-year growth of 2.31% [2] - The company has a debt ratio of 25.1% and reported investment income of 41.22 million yuan, with financial expenses amounting to 31.93 million yuan and a gross profit margin of 41.69% [2] Group 3 - The stock experienced a net outflow of 19.18 million yuan from main funds, accounting for 11.06% of the total transaction amount, while retail investors saw a net inflow of 11.71 million yuan, representing 6.75% of the total [1] - Over the past 90 days, seven institutions have provided ratings for the stock, with four giving a buy rating and three an increase rating, while the average target price set by institutions is 5.29 billion yuan [2]

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-26 | 40.93 0.17% | | -2139.93万 | -13.49% | -693.58万 | -4.37% | 2833.51万 | - 17.86% | | 2025-12-25 | 40.86 | -0.39% | -1366.25万 | -9.81% | 697.95万 | 5.01% | 668.30万 | 4.80% | | 2025-12-24 | 41.02 0.84% | | -865.51万 | -6.83% | -135.55万 | -1.07% | 1001.06万 | 7.90% | | 2025-12-23 | 40.68 -0.83% | | -1464.22万 | -11.77% | -849.09万 | -6.82% | 2313.31万 | 18.59% | | 2025-12-22 | 41.02 -0.70% ...

从资金流向上来看，当日医疗服务板块主力资金净流出8.24亿元，游资资金净流入4129.99万元，散户资 金净流入7.83亿元。医疗服务板块个股资金流向见下表： 证券之星消息，12月26日医疗服务板块较上一交易日下跌0.21%，皓元医药领跌。当日上证指数报收于 3963.68，上涨0.1%。深证成指报收于13603.89，上涨0.54%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600721 | 自花医药 | 12.24 | 5.88% | 48.95万 | | 5.94亿 | | 301096 | 百诚医药 | 55.93 | 3.79% | 5.12万 | | 2.84亿 | | 000504 | *ST生物 | 9.20 | 3.25% | 2.70万 | | 2461.38万 | | 301201 | 诚达药业 | 41.95 | 0.84% | 6.37万 | | 2.72亿 | | 603259 | 药明康德 | 92.70 | 0. ...

证券之星消息，截至2025年12月23日收盘，通策医疗(600763)报收于40.68元，下跌0.83%，换手率 0.68%，成交量3.05万手，成交额1.24亿元。 12月23日的资金流向数据方面，主力资金净流出1464.22万元，占总成交额11.77%，游资资金净流出 849.09万元，占总成交额6.82%，散户资金净流入2313.31万元，占总成交额18.59%。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 通策医疗2025年三季报显示，前三季度公司主营收入22.9 ...

证券之星消息，截至2025年12月18日收盘，通策医疗(600763)报收于41.06元，上涨0.61%，换手率 0.87%，成交量3.89万手，成交额1.59亿元。 12月18日的资金流向数据方面，主力资金净流出1160.26万元，占总成交额7.28%，游资资金净流出 662.48万元，占总成交额4.16%，散户资金净流入1822.74万元，占总成交额11.43%。 近5日资金流向一览见下表： 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同比上升3.09%；其中2025年第三季度，公司单季度主营收 入8.42亿元，同比上升2.34%；单季度归母净利润1.92亿元，同比上升2.31%；单季度扣非净利润1.92亿 元，同比上升1.85%；负债率25.1%，投资收益4122.43万元，财务费用3192.82万元，毛利率41.69%。通 策医疗（600763）主营业务：医疗服务。 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.88。 资金流向名词解释：指 ...

Core Viewpoint - Tongce Medical (600763) is focused on providing medical services as a dental healthcare group, emphasizing the significant potential of the domestic market in China [1] Group 1: Company Strategy - The company aims to deepen its presence in the domestic dental healthcare service market [1] - It is committed to strengthening its leading position in Zhejiang Province [1] - The company is steadily advancing its layout in key regions across the country [1]

Group 1 - The core viewpoint of the article is that Tongce Medical (600763) has disclosed its total number of shareholders, which is 98,000 as of December 10, 2025 [1] - The company emphasizes the importance of fair information access for all investors and states that future updates on shareholder numbers will be provided in its official periodic reports [1]

Core Viewpoint - Tongce Medical (600763) reported a slight decline in stock price, with a closing price of 40.25 yuan on December 15, 2025, down 0.57% [1] Financial Performance - For the first three quarters of 2025, Tongce Medical achieved a main revenue of 2.29 billion yuan, an increase of 2.56% year-on-year [2] - The net profit attributable to shareholders was 514 million yuan, up 3.16% year-on-year, while the net profit excluding non-recurring items was 509 million yuan, increasing by 3.09% year-on-year [2] - In Q3 2025, the company reported a single-quarter main revenue of 842 million yuan, a year-on-year increase of 2.34% [2] - The single-quarter net profit attributable to shareholders was 192 million yuan, up 2.31% year-on-year, and the net profit excluding non-recurring items was also 192 million yuan, increasing by 1.85% year-on-year [2] - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan [2] - The gross profit margin is reported at 41.69% [2] Market Activity - On December 15, 2025, the net inflow of main funds was 1.6042 million yuan, accounting for 1.15% of the total transaction amount, while retail funds saw a net inflow of 9.405 million yuan, making up 6.74% of the total transaction amount [1] - Conversely, speculative funds experienced a net outflow of 11.0092 million yuan, representing 7.89% of the total transaction amount [1] Analyst Ratings - In the last 90 days, seven institutions provided ratings for Tongce Medical, with four giving a "buy" rating and three an "increase" rating [2] - The average target price set by institutions over the past 90 days is 5.288 billion yuan [2]